ALX Oncology Q1 2026 net loss narrows to $17.9M; evorpacept data shows durable responses

ALX ONCOLOGY HOLDINGS INC

2026-Q1 EPS reported -$0.17

GAAP net loss of $17.9M ($0.17/sh) vs $30.8M ($0.58/sh) YoY; R&D expenses down to $13.6M.
Cash $169.1M at March 31, 2026; expects to fund operations through first half of 2028.
Phase 1b/2 evorpacept + zanidatamab data: 60% cORR in ccHER2+ patients; all 5 with high CD47 responded (mPFS 22.1 months).
Phase 2 ASPEN-09-Breast topline data in mid-2027; Phase 1 ALX2004 safety data in 2H 2026.
Appointed Jeff Knight as Chief Development and Operating Officer in April 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ALX ONCOLOGY HOLDINGS INC reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 8, 2026, ALX Oncology Holdings Inc. (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-213380

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.